• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Lack of superiority of rivaroxaban for secondary prevention of embolic stroke of undetermined source

byIyas DaghlasandDayton McMillan
June 19, 2018
in Cardiology, Chronic Disease, Emergency, Imaging and Intervention, Neurology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. At a median follow-up of eleven months, rivaroxaban was not superior to aspirin for prevention of secondary stroke after an initial primary embolic stroke of undetermined source.

2. Use of rivaroxaban was associated with a higher rate of major bleeding relative to aspirin.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Improvements in medical diagnostics have led to the identification of the likely etiology of stroke in most cases. The twenty percent of strokes for which a source cannot be identified are termed cryptogenic. It has been hypothesized that some of these strokes could be embolic in origin, therefore treatment with an anticoagulant might reduce risk of recurrent stroke. The investigators of this study tested this hypothesis by randomizing participants with considered to have an initial embolic stroke of undetermined source to either aspirin 100mg or rivaroxaban 15mg daily and followed them for a median of eleven months to determine efficacy of all-cause stroke risk reduction. They found no evidence of a difference between the two drugs regarding secondary stroke prevention. Rivaroxaban was associated with a significantly higher risk of major bleeding. These data do not support the use of rivaroxaban over aspirin in patients with embolic strokes of undetermined source.

A major strength of this study is the randomized controlled design and determination of adherence via interviews and pill counts. One weakness is that intracranial imaging was optional, therefore the trial might have included patients with stenosis of intracranial vessels as the etiology of their stroke who would theoretically not benefit from anticoagulation.

Click to read the study in NEJM

Relevant Reading: Embolic strokes of undetermined source: the case for a new clinical construct

RELATED REPORTS

#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants

Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

In-Depth [randomized controlled trial]: This was an international, multicenter, randomized controlled trial that randomized 7213 participants to either aspirin 100mg (n = 3604) or rivaroxaban 15mg (n = 3609) daily. Inclusion criteria included age greater than 49 and the occurrence of ischemic stroke identified by imaging seven days to six months before screening. Strokes that were lacunar, associated with extracranial vessel atherosclerosis >50%, or with a known risk factor for cardiac embolism were excluded (with at least 20 hours of cardiac rhythm monitoring). Imaging of intracranial vessels was not required, but if >50% stenosis was identified those strokes were excluded. Initial strokes resulting in severe disablement were excluded. The primary outcome was first recurrent ischemic or hemorrhagic stroke or systemic embolism of any etiology and was evaluated in a time-to-event manner. A primary safety outcome was occurrence of major bleeding.

At a median of eleven months follow-up the investigators found no evidence of difference in rates of secondary stroke between rivaroxaban or aspirin treated patients (hazard ratio [HR], 1.07; 95% confidence interval [CI], 0.87 to 1.33, p = 0.52). Rates of major bleeding were higher in the rivaroxaban (annualized rate, 1.8%) compared to aspirin group (annualized rate, 0.7%; HR, 2.72; 95% CI, 1.68 to 4.39; p < 0.001). A secondary outcome of death from any cause showed no significant difference between the two groups.

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: embolizationischemic strokerivaroxaban
Previous Post

Prognosis of extremely premature infants linked to inherent selection bias

Next Post

Failures in using personal protective equipment are commonly observed

RelatedReports

#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes
StudyGraphics

#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

November 24, 2022
Blood type correlates with egg reserve in infertile women
Cardiology

Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants

November 17, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

November 15, 2022
Quick Take: Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse
Cardiology

Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease

October 31, 2022
Next Post
Contamination during personal protective equipment removal may be common

Failures in using personal protective equipment are commonly observed

Few older adolescents meet recommended levels of physical activity

Disparities in adolescent physical activity between sex, race, and income

Prenatal antidepressant exposure may increase risk of poor motor development

Prenatal antidepressant exposure may increase risk of poor motor development

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options